DB-OTO
DB-OTO is an experimental gene therapy for otoferlin-related hearing loss developed by Regeneron Pharmaceuticals. It is delivered via adeno-associated virus.[1][2][3][4][5][6]
References
[edit]- ^ Le Prell, Colleen G. (3 August 2023). "Preclinical prospects of investigational agents for hearing loss treatment". Expert Opinion on Investigational Drugs. 32 (8): 685–692. doi:10.1080/13543784.2023.2253141. PMID 37695693. S2CID 261694986.
- ^ Philippidis, Alex (1 December 2020). "Bayer, Novartis, Pfizer Raise Big Pharma's Stake in Gene Therapy". Human Gene Therapy. 31 (23–24): 1221–1223. doi:10.1089/hum.2020.29142.bfs. PMID 33337268. S2CID 229316419.
- ^ Philippidis, Alex (1 January 2023). "StockWatch: Regeneron's All Ears for Hearing Loss Drug Developer: With planned up-to-$213M buyout, Decibel joins a growing number of biotechs focused on treating ear disorders to find a buyer". GEN Edge. 5 (1): 542–548. doi:10.1089/genedge.5.1.105. S2CID 265960410.
- ^ Jiang, Luoying; Wang, Daqi; He, Yingzi; Shu, Yilai (April 2023). "Advances in gene therapy hold promise for treating hereditary hearing loss". Molecular Therapy. 31 (4): 934–950. doi:10.1016/j.ymthe.2023.02.001. PMC 10124073. PMID 36755494.
- ^ Development of an AAV-Based Gene Therapy for Children with Congenital Hearing Loss Due to Otoferlin Deficiency (DB-OTO). Source: Journal of Hearing Science . 2022, Vol. 12 Issue 1, p76-76. 1/4p. Author(s): De Raeve, L.; Holcomb, M.; Ramos Macías, A.
- ^ Hayward, Eleanor (2024-05-09). "Toddler born deaf can hear after world-first gene therapy". The Times. ISSN 0140-0460. Retrieved 2024-05-09.